Thursday, June 19th, 2025
Stock Profile: VCYT

Veracyte, Inc. (VCYT)

Market: NASD | Currency: USD

Address: 6000 Shoreline Court

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was Show more




📈 Veracyte, Inc. Historical Chart






📊 Statistics





💰 Dividend History


No dividend history available.



📅 Earnings & EPS History for Veracyte, Inc.


DateReported EPS
2026-02-23 (estimated upcoming)-
2025-11-04 (estimated upcoming)-
2025-08-04 (estimated upcoming)-
2025-05-070.09
2025-02-240.06
2024-11-060.19
2024-08-060.07
2024-05-07-0.02
2024-02-22-0.39
2023-11-07-0.41
2023-08-08-0.12
2023-05-04-0.11
2023-02-22-0.05
2022-11-02-0.12
2022-08-02-0.13
2022-05-03-0.2
2022-02-28-0.15
2021-11-09-0.2
2021-07-29-0.13
2021-05-10-0.11
2021-02-17-0.14
2020-11-02-0.08
2020-07-30-0.22
2020-05-06-0.24
2020-02-25-0.15




📰 Related News & Research


No related articles found for "veracyte inc".